ly 300164 has been researched along with 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline in 6 studies
Studies (ly 300164) | Trials (ly 300164) | Recent Studies (post-2010) (ly 300164) | Studies (2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline) | Trials (2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline) | Recent Studies (post-2010) (2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline) |
---|---|---|---|---|---|
73 | 7 | 12 | 1,216 | 0 | 229 |
Protein | Taxonomy | ly 300164 (IC50) | 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline (IC50) |
---|---|---|---|
Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.5781 | |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.5781 | |
Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.5781 | |
Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.5781 | |
Glutamate receptor ionotropic, kainate 1 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, kainate 2 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor 1 | Homo sapiens (human) | 6 | |
Glutamate receptor 2 | Homo sapiens (human) | 2.5 | |
Glutamate receptor 3 | Homo sapiens (human) | 1.9 | |
Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor 4 | Homo sapiens (human) | 1.1 | |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, kainate 4 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, kainate 5 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cagnotto, A; Colleoni, S; Diana, V; Grasso, S; Lazzaro, J; Mennini, T; Micale, N; Pellicanò, A; Postorino, G; Zappalà , M | 1 |
Carcache, D; Kalkman, HO; Koller, M; Mattes, H | 1 |
Deverill, M; Hoo, KH; Iyengar, S; Li, DL; Ornstein, PL; Simmons, RM | 1 |
Jiang, L; Kang, J; Nedergaard, M; Xu, J | 1 |
Barkoczy, J; Gigler, G; Gressens, P; Harsing, LG; Kapus, G; Kertesz, S; Levay, G; Medja, F; Spedding, M; Szenasi, G; Villa, P; Williamson, T | 1 |
Aujla, PK; Fishman, R; Jensen, FE; Rakhade, SN; Sucher, NJ; Zhou, C | 1 |
6 other study(ies) available for ly 300164 and 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
Article | Year |
---|---|
Structure-activity study of 2,3-benzodiazepin-4-ones noncompetitive AMPAR antagonists: identification of the 1-(4-amino-3-methylphenyl)-3,5-dihydro-7,8-ethylenedioxy-4H-2,3-benzodiazepin-4-one as neuroprotective agent.
Topics: Animals; Benzodiazepines; Benzodiazepinones; Calcium; Cells, Cultured; Hippocampus; Inhibitory Concentration 50; Kainic Acid; Ligands; Mice; Molecular Structure; Neurons; Neuroprotective Agents; Protein Binding; Receptors, AMPA; Structure-Activity Relationship | 2008 |
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
Topics: Analgesics; Animals; Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Protein Subunits; Receptors, AMPA | 2010 |
Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat.
Topics: Animals; Benzodiazepines; Excitatory Amino Acid Antagonists; Formaldehyde; Humans; Isoquinolines; Male; Pain Threshold; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Kainic Acid; Tetrazoles | 1998 |
A kainate receptor increases the efficacy of GABAergic synapses.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Benzoates; Benzodiazepines; Cyclic AMP-Dependent Protein Kinases; Enzyme Inhibitors; Evoked Potentials; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Glycine; Hippocampus; In Vitro Techniques; Interneurons; Kainic Acid; Neurons; Protein Kinase C; Pyramidal Cells; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Kainic Acid; Staurosporine; Synapses; Tetradecanoylphorbol Acetate; Tetrodotoxin | 2001 |
The effects of AMPA receptor antagonists in models of stroke and neurodegeneration.
Topics: Animals; Animals, Newborn; Anticonvulsants; Benzodiazepines; Brain; Brain Ischemia; Cell Survival; Chickens; Cortical Spreading Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Excitatory Amino Acid Antagonists; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred Strains; Motor Neurons; Nerve Degeneration; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Retina; Seizures; Stroke | 2005 |
Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures.
Topics: Animals; Animals, Newborn; Anticonvulsants; Benzodiazepines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP-Dependent Protein Kinases; Disease Susceptibility; Enzyme Activation; Epilepsy; Excitatory Postsynaptic Potentials; Fructose; Hypoxia; Male; Phosphorylation; Protein Kinase C; Quinoxalines; Rats; Rats, Long-Evans; Receptors, AMPA; Synapses; Topiramate | 2008 |